{"filing":{"accession_number":"0001104659-26-097180","cik":"0001137883","ticker":"BCLI","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623188d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/tm2623188d1_8k.htm"},"events":[{"id":27929,"run_id":25506,"accession_number":"0001104659-26-097180","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including net loss of $3.9 million, cash position of $0.2 million, and operating expenses. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The filing includes consolidated balance sheet and comprehensive loss statements for the period.","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29654,"accession_number":"0001104659-26-097180","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including net loss of $3.9 million, cash position of $0.2 million, and operating expenses. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The filing includes consolidated balance sheet and comprehensive loss statements for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:29:54.650640+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29654,"accession_number":"0001104659-26-097180","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including net loss of $3.9 million, cash position of $0.2 million, and operating expenses. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The filing includes consolidated balance sheet and comprehensive loss statements for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:29:54.650640+00:00","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-08-14"}]}